Evidence map›Paper›PMID 33369010›Full record

ArticleJournal of cellular and molecular medicine2021

N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide is a novel inhibitor of resorptive bone loss in mice.

Zhihao Chen, Eunjin Cho, Mina Ding, Jihyoun Seong, Xiangguo Che, Sunwoo Lee, Byung-Ju Park, Je-Yong Choi, Tae-Hoon Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Zhihao ChenDepartment of Molecular Medicine, Chonnam National University Graduate School, Gwangju, Korea.ORCID 0000-0002-8433-5400
Eunjin ChoDepartment of Oral Biochemistry, Dental Science Research Institute, Korea Mouse Phenotyping Center, School of Dentistry, Chonnam National University, Gwangju, Korea.
Mina DingDepartment of Molecular Medicine, Chonnam National University Graduate School, Gwangju, Korea.
Jihyoun SeongDepartment of Oral Biochemistry, Dental Science Research Institute, Korea Mouse Phenotyping Center, School of Dentistry, Chonnam National University, Gwangju, Korea.
Xiangguo CheDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, Korea Mouse Phenotyping Center, KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu, Korea.
Sunwoo LeeDepartment of Chemistry, Chonnam National University, Gwangju, Korea.
Byung-Ju ParkDepartment of Oral Biochemistry, Dental Science Research Institute, Korea Mouse Phenotyping Center, School of Dentistry, Chonnam National University, Gwangju, Korea.
Je-Yong ChoiDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, Korea Mouse Phenotyping Center, KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu, Korea.
Tae-Hoon LeeDepartment of Molecular Medicine, Chonnam National University Graduate School, Gwangju, Korea.ORCID 0000-0003-0105-1750
Chonnam National University · KRKyungpook National University · KR

Funding

Ministry of Science, ICT & Future Planning NRF-2016M3A9B6903087National Research Foundation NRF-2014M3A9D5A01073658
6 · The paper itself

Abstract

The dynamic balance between bone formation and bone resorption is vital for the retention of bone mass. The abnormal activation of osteoclasts, unique cells that degrade the bone matrix, may result in many bone diseases such as osteoporosis. Osteoporosis, a bone metabolism disease, occurs when extreme osteoclast-mediated bone resorption outstrips osteoblast-related bone synthesis. Therefore, it is of great interest to identify agents that can regulate the activity of osteoclasts and prevent bone loss-induced bone diseases. In this study, we found that N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide (PPOAC-Bz) exerted a strong inhibitory effect on osteoclastogenesis. PPOAC-Bz altered the mRNA expressions of several osteoclast-specific marker genes and blocked the formation of mature osteoclasts, suppressing F-actin belt formation and bone resorption activity in vitro. In addition, PPOAC-Bz prevented OVX-induced bone loss in vivo. These findings highlighted the potential of PPOAC-Bz as a prospective drug for the treatment of osteolytic disorders.

Indexed as

AcetamidesAnimalsBone Density Conservation AgentsBone ResorptionCells, CulturedDisease Models, AnimalMiceOsteogenesisOsteoporosisRANK LigandSeverity of Illness IndexX-Ray MicrotomographyAcetamidesBone Density Conservation AgentsRANK Ligandacetamidebone resorptionosteoclastogenesispiperazine

Identifiers

PMID33369010
PMCPMC7875930
OpenAlexW3115676213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.